JP2013516194A5 - - Google Patents

Download PDF

Info

Publication number
JP2013516194A5
JP2013516194A5 JP2012548181A JP2012548181A JP2013516194A5 JP 2013516194 A5 JP2013516194 A5 JP 2013516194A5 JP 2012548181 A JP2012548181 A JP 2012548181A JP 2012548181 A JP2012548181 A JP 2012548181A JP 2013516194 A5 JP2013516194 A5 JP 2013516194A5
Authority
JP
Japan
Prior art keywords
cell
cells
nucleic acid
promoter
transduced
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012548181A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013516194A (ja
JP5873807B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/020578 external-priority patent/WO2011085247A2/en
Publication of JP2013516194A publication Critical patent/JP2013516194A/ja
Publication of JP2013516194A5 publication Critical patent/JP2013516194A5/ja
Application granted granted Critical
Publication of JP5873807B2 publication Critical patent/JP5873807B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012548181A 2010-01-08 2011-01-07 B細胞を形質導入するためのベクターおよび方法 Active JP5873807B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29352210P 2010-01-08 2010-01-08
US61/293,522 2010-01-08
PCT/US2011/020578 WO2011085247A2 (en) 2010-01-08 2011-01-07 Vectors and methods for transducing b cells

Publications (3)

Publication Number Publication Date
JP2013516194A JP2013516194A (ja) 2013-05-13
JP2013516194A5 true JP2013516194A5 (cg-RX-API-DMAC7.html) 2014-02-27
JP5873807B2 JP5873807B2 (ja) 2016-03-01

Family

ID=44306176

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012548181A Active JP5873807B2 (ja) 2010-01-08 2011-01-07 B細胞を形質導入するためのベクターおよび方法

Country Status (7)

Country Link
US (1) US9074223B2 (cg-RX-API-DMAC7.html)
EP (1) EP2521789B1 (cg-RX-API-DMAC7.html)
JP (1) JP5873807B2 (cg-RX-API-DMAC7.html)
CA (1) CA2786664C (cg-RX-API-DMAC7.html)
DK (1) DK2521789T3 (cg-RX-API-DMAC7.html)
ES (1) ES2617749T3 (cg-RX-API-DMAC7.html)
WO (1) WO2011085247A2 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104080805B (zh) * 2011-11-07 2017-02-22 美国政府健康及人类服务部 gp41中和性抗体及其用途
ES2786253T3 (es) * 2013-03-14 2020-10-09 Immusoft Corp Métodos para la diferenciación y transducción in vitro de células b de memoria con vectores virales pseudotipados vsv-g
US20160075766A1 (en) 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
JP6568207B2 (ja) * 2014-05-19 2019-08-28 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ヒツジb細胞を用いて抗体を産生するための方法およびその使用
EP4177336A1 (en) 2014-12-19 2023-05-10 Immusoft Corporation B cells for in vivo delivery of therapeutic agents
CA2981077A1 (en) * 2015-04-03 2016-10-06 Dana-Farber Cancer Institute, Inc. Composition and methods of genome editing of b-cells
EP3417052B1 (en) * 2016-02-16 2023-02-15 Duke University Methods for expanding and differentiating b cells for producing antibody
JP2020517692A (ja) * 2017-04-27 2020-06-18 イミュソフト コーポレーション 治療剤のin vivo送達のためのB細胞およびその投薬量
CN119265240A (zh) * 2017-10-20 2025-01-07 弗莱德哈钦森癌症中心 用以产生被遗传修饰来表达所选抗体的b细胞的系统和方法
CA3093716A1 (en) 2018-03-16 2019-09-19 Immusoft Corporation B cells genetically engineered to secrete follistatin and methods of using the same to treat follistatin-related diseases, conditions, disorders and to enhance muscle growth and strength
RU2714380C1 (ru) * 2018-12-28 2020-02-14 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения цитотоксических т-лимфоцитов, экспрессирующих химерные рецепторы
CA3136551A1 (en) * 2019-04-12 2020-10-15 Board Of Regents, The University Of Texas System Methods for producing regulatory b cells and uses thereof
WO2021154993A1 (en) * 2020-01-28 2021-08-05 University Of Southern California Genome engineering the human immunoglobulin locus to express recombinant binding domain molecules
CA3192356A1 (en) * 2020-08-17 2022-02-24 Northwestern University B-cell based immunotherapy for the treatment of glioblastoma and other cancers
US20250152714A1 (en) 2023-11-15 2025-05-15 Immusoft Corporation Migratory modified differentiated b cells for cancer therapy
WO2025147573A2 (en) 2024-01-05 2025-07-10 Immusoft Corporation Glp-1 expressing modified b cells for the treatment of metabolic disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US6218181B1 (en) 1998-03-18 2001-04-17 The Salk Institute For Biological Studies Retroviral packaging cell line
CA2413995C (en) 2000-06-01 2013-08-13 Dnavec Research Inc. Pseudotype retroviral vectors containing membrane proteins having hemagglutinin activity
WO2003068819A1 (en) * 2001-12-22 2003-08-21 4-Antibody Ag Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
EP1975239A1 (en) 2006-09-27 2008-10-01 Bundesrepublik Deutschland, letztvertreten durch den Präsidenten des Paul-Ehrlich-Instituts Prof. Dr. Johannes Löwer Pseudotyping of retroviral vectors, methods for production and use thereof for targeted gene transfer and high-throughput screening
US8133727B2 (en) 2008-11-21 2012-03-13 California Institute Of Technology In vitro human B lymphopoiesis culture system

Similar Documents

Publication Publication Date Title
US10829566B2 (en) Method employing bispecific antibodies
JP7264329B2 (ja) T細胞療法を向上させるための、哺乳動物t細胞の活性化により誘導可能な合成プロモーター(syn+pro)の作製
WO2015155370A4 (en) Group b adenovirus modified in the e4orf4 region
JP2019508017A5 (cg-RX-API-DMAC7.html)
JP2016025858A5 (cg-RX-API-DMAC7.html)
JP2021534829A5 (cg-RX-API-DMAC7.html)
JP2019534036A5 (cg-RX-API-DMAC7.html)
JP2012504959A5 (cg-RX-API-DMAC7.html)
WO2011085247A4 (en) Vectors and methods for transducing b cells
CN120513099A (zh) 巨噬细胞特异性启动子和其用途
JP2024515263A5 (cg-RX-API-DMAC7.html)
US20230100000A1 (en) Immune cell expressing adapter chimeric antigen receptor for sensing soluble antigens
CN109306340B (zh) 一种高效扩增全t细胞的人工抗原递呈细胞及其用途
JP2025118760A (ja) 細胞の選択方法
JP2023532665A (ja) 核酸の標的化組み込み
JP2024533328A (ja) 誘導性プロモーター、それに基づくベクターおよび宿主細胞
CN112458116B (zh) 一种pd-1敲除的cd19car-t细胞的构建方法
US20240415891A1 (en) Activation responsive promoters and uses thereof
JP2026511057A (ja) Ccl20プロモーター調節遺伝子発現
TW202544250A (zh) 巨噬細胞特異性啟動子及其用途
TW202400789A (zh) Eno1基因的啟動子
WO2025084267A1 (ja) 形質転換体及び目的タンパク質の生産方法
KR20260035834A (ko) 개선된 다중시스트론성 시스템 및 이의 용도
CN121986170A (zh) 工程化调控元件
HK40113432A (en) Inducible promoter, vector and host cell based thereon